Concord Biotech (BOM:543960) Accounts Payable: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543960 Concord Biotech Ltd BOM:543960
90 GF Score
Price ₹1,414.75
GF Value ₹1,693.45
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Concord Biotech Accounts Payable?

Concord Biotech BOM:543960 -2.33% 90 Accounts Payable is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:543960 with a GF Score™ of 90/100 and a GF Value™ of ₹1,693.45 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Concord Biotech's Accounts Payable for the quarter that ended in Jun. 2026 was ₹0 Mil.

Concord Biotech's quarterly Accounts Payable increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹1,019 Mil) but then declined from Mar. 2026 (₹1,019 Mil) to Jun. 2026 (₹0 Mil).

Concord Biotech's annual Accounts Payable increased from Mar. 2024 (₹944 Mil) to Mar. 2025 (₹1,130 Mil) but then declined from Mar. 2025 (₹1,130 Mil) to Mar. 2026 (₹1,019 Mil).

Concord Biotech Accounts Payable Related Terms

Concord Biotech Accounts Payable Historical Data

* Premium members only.

The historical data trend for Concord Biotech's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Biotech Accounts Payable Chart

Concord Biotech Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial 831.06 938.00 944.35 1,130.40 1,019.09

Concord Biotech Quarterly Data
Mar20 Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 865.85 0.00 1,019.09 0.00
BOM:543960
90GF Score
Concord Biotech Ltd BOM:543960
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Biotech Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹0 Mil mean?
Concord Biotech (BOM:543960) has a Accounts Payable of ₹0 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Concord Biotech and its competitors.
Is Concord Biotech's Accounts Payable too high?
Concord Biotech's current Accounts Payable is ₹0 Mil. Overall, Concord Biotech has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Accounts Payable compare to VRTX and REGN?
Concord Biotech's Accounts Payable of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Concord Biotech and its competitors. Concord Biotech's current Accounts Payable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,693.45, compared to a current price of ₹1,414.75 — trading 16.5% below its estimated fair value. The current Accounts Payable is ₹0 Mil. Concord Biotech's overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current Accounts Payable is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Biotech (BOM:543960) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued. The current stock price of ₹1,414.75 is trading 16.5% below its estimated GF Value™ of ₹1,693.45. GuruFocus considers Concord Biotech to be Modestly Undervalued.

Key valuation signals for BOM:543960:

  • Accounts Payable: ₹0 Mil
  • GF Value™: ₹1,693.45 vs. price of ₹1,414.75 (16.5% below fair value)
  • GF Score™: 90/100 with 7 warning signs

No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Biotech Business Description

Other Exchanges CONCORDBIO:India
Address Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
90GF Score

Get the complete analysis for BOM:543960

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,414.75
Price
₹1,693.45
GF Value